Pretreatment immune status correlates with progression-free survival in chemotherapy- Treated metastatic colorectal cancer patients

Cancer Immunology Research

Volumn 4, Issue 7, 2016, Pages 592-599

  Tada, Kohei ^a,b,c   Kitano, Shigehisa ^a,d   Shoji, Hirokazu ^a   Nishimura, Takashi ^e   Shimada, Yasuhiro ^a   Nagashima, Kengo ^f   Aoki, Kazunori ^g   Hiraoka, Nobuyoshi ^g   Kahonma, Yoshita ^a   Iwasa, Satoru ^a   Okita, Natsuko ^a   Takashima, Atsuo ^a   Kato, Ken ^a   Yamada, Yasuhide ^a   Katayama, Naoyuki ^b   Boku, Narikazu ^a   Heike, Yuji ^a,c   Hamaguchi, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHIBA UNIVERSITY   (Japan)

^g NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GRANZYME B; KI 67 ANTIGEN; OXALIPLATIN; PERFORIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; IMMUNE STATUS; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; METASTATIC COLORECTAL CANCER; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; CANCER STAGING; COLORECTAL TUMOR; CYTOLOGY; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNITY; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84979783845     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0298     Document Type: Article

References (33)

1. House AK, Watt AG. Survival and the immune response in patients with carcinoma of the colorectum. Gut 1979;20:868-74.
2. Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: The first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology 2015;4:e1058597.
3. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-7.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
5. Halvorsen TB, Seim E. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol 1989;42:162-6.
6. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986;39:585-9.
7. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab Invest 2004;84: 493-501.
8. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29: 610-8.
9. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8 T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
10. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8 tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-16.
11. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
12. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
13. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-51.
14. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012;12: 298-306.
15. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
16. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, et al. Increase in CD14HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013;62:1421-30.
17. Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, et al. Infiltrating S100A8myeloid cells promotemetastatic spread of human breast cancer and predict poor clinical outcome. Breast Cancer Res Treat 2014;148: 41-59.
18. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30.
19. Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, et al. Computational algorithm-driven evaluation of monocytic myeloidderived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014;2:812-21.
20. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61.
21. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment ofmetastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523-9.
22. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12.
23. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012;381:14-22.
24. Grambsch PM, Tm T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
25. Hosmer DW, Lemeshow S, May S. Applied survival analysis: Regression modeling of time- To-event data. 2nd ed. New York (NY): Wiley; 2008.
26. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumorinfiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
27. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013;73:2943-8.
28. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
29. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007;110:624-31.
30. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-32.
31. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005;174:215-22.
32. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer 2012;130: 857-64.
33. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8 T cells in tumors. J Exp Med 2015;212:139-48.